Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

138.70
+0.08000.06%
Post-market: 139.200.5000+0.36%19:46 EDT
Volume:1.89M
Turnover:263.70M
Market Cap:264.64B
PE:20.97
High:141.46
Open:140.58
Low:138.28
Close:138.62
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:0.75
T/O Rate:0.10%
Dividend:4.67
Dividend Rate:3.36%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:6.37
PE(LYR):19.40

Loading ...

Movement Alert|Novartis AG Falls 4.16% Overnight, Phase III Heart Disease Drug Pelacarsen Fails Key Cardiovascular Trial

Market Focus
·
Sep 08

European Equities Remain Flat as Energy Gains Offset by Pharma Slump

Deep News
·
Sep 08

Novartis AG Falls Monday, Underperforms Market

Dow Jones
·
Sep 08

Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321

TIPRANKS
·
Sep 07

Citi sees limited immediate downside for Ionis after pelacarsen failure

TIPRANKS
·
Sep 07

BofA sees low single-digit percentage downside for Novartis on pelacarsen miss

TIPRANKS
·
Sep 07

Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial

Dow Jones
·
Sep 07

Novartis India to Acquire 'Minipress' Trademarks from Pfizer

Reuters
·
Sep 07

Second Clinical Trial Blow in a Week for Novartis as Heart Drug Disappoints, Dragging Down Amgen Shares

Stock News
·
Sep 07

Novartis Heart-Trial Failure Could be Mitigated by Investor Caution

Dow Jones
·
Sep 07

Novartis India - Deal Valued at 12.50 Bln Rupees

THOMSON REUTERS
·
Sep 07

Novartis Shares to Take Hit from Cholesterol Trial Failure

Dow Jones
·
Sep 07

Dow Jones Top Company Headlines at 9 PM ET: Amazon Cargo Plane Overshoots Runway in Miami, Killing Five People | Carmakers ...

Dow Jones
·
Sep 07

A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?

Dow Jones
·
Sep 06

Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal

Dow Jones
·
Sep 05

Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex

Dow Jones
·
Sep 05

Novartis Pelacarsen Fails Phase III Cardiovascular Outcomes Trial

MT Newswires Live
·
Sep 05

Novartis announces Phase 3 pelacarsen study did not meet primary endpoint

TIPRANKS
·
Sep 05

Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint

Dow Jones
·
Sep 05

Movement Alert|Novartis AG Falls 6.24% in After-Hours Trading, Trading at $154.33

Market Focus
·
Sep 05